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INTRODUCTION
Hepatitis B virus reactivation (HBVr) is increasingly recognized 
as a clinical problem and has associated significant morbidity 
and mortality. Conversely, the International Guidelines for HBV 
screening in patients undergoing immunosuppressive drug therapy 
(ISDT) are controversial: The American Association for the 
Study of Liver Diseases guidelines recommend both HBsAg and 
antiHBc testing in patients who are at high risk of HBV infection 
prior to initiation of ISDT[1], The European Association for the 
Study of the Liver guidelines recommend that all candidates 
to ISDT should be screened for HBsAg and antiHBc prior to 
initiation of treatment[2], The Asian Pacific Association for the 
Study of the Liver recommends that patients who are going 
to receive biological agent such as anti-CD 20 or anti-tumor 
necrosis factor should be screened for both HBsAg and antiHBc. 
In case of antiHBc positivity, HBV-DNA should be closely 
monitored and treatment with nucleoside/nucleotide analogue 
(NA) should be started when needed[3]. Recently, the American 
Gastroenterological Association guidelines recommend screening 
for HBV (HBsAg and antiHBc, followed by a sensitive HBV-
DNA test in case of positivity for either one or the other test, or 
both tests) in patients at moderate or high risk who will undergo 
ISDT, so the HBV screening may be cost-effective in patients 
with breast cancer slated to receive adjuvant chemotherapy if 
HBV infection is prevalent[4]. 
    About 20% of untreated HBsAg-positive patients with breast 
cancer undergoing chemoteraphy develop HBVr, in these studies 
anthracycline-based therapy was used by all investigators[5-7] and 
glucocorticoids were routinely administered in 2 studies. Despite 
in literature capecitabine does not result in acute hepatitis B 
reactivation[8]; we report a case of HBVr leading to exitus in a female 
patient with breast cancer treated using capecitabine.
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ABSTRACT
Reactivation of hepatitis B virus (HBV) is a well-recognized 
complication following immunosuppressive drug therapy in patients 
with past infection. The International Guidelines for HBV screening 
before cytotoxic or immunosuppressive therapy are controversial, there 
is only agreement on the use of biological agent such as anti-CD 20. 
The literature data do not report HBV reactivation due to capecitabine 
and therefore the international guidelines do not recommend 
prophylaxis in that condition. In this paper, we describe the history 
of HBV reactivation of hepatitis B in a female patient with breast 
cancer treated using capecitabine observed in a Unit of Infectious 
Diseases of north-est of Italy.
© 2016 The Authors. Published by ACT Publishing Group Ltd.
Key Words: Hepatitis B virus reactivation (HBVr); Capecitabine; 
breast cancer; Tenofovir; Immunosuppressive drug therapy (ISDT); 
Acute liver failure (ALF)
Fiore M, Crosato IM, Bussani R, Valentinotti R, Mascarello M, 
Luzzati R. Reactivation of Hepatitis B in a Patient with Breast 
Cancer Treated Using Capecitabine. Journal of Gastroenterology 
CASE REPORT
Reactivation of Hepatitis B in a Patient with Breast Cancer 
Treated Using Capecitabine
Marco Fiore, Ivo Maria Crosato, Rossana Bussani, Romina Valentinotti, Marta Mascarello, Roberto Luzzati
2038
Journal of GHR 2016; 5(2): 2038-2040
 ISSN 2224-3992 (print)  ISSN 2224-6509 (online)
Online Submissions: http: //www.ghrnet.org/index./joghr/
doi: 10.17554/j.issn.2224-3992.2016.05.631
                                
                                  Journal of                                       Gastroenterology and Hepatology Research                      
2039
Fiore M et al . Capecitabine associated HBV-reactivation
Figure 1 Clinical course characterized by a progressive increase of the 
indices of hepatic necrosis. AST: Aspartate aminotransferase; ALT: Alanine 
aminotransferase; TBIL: Total bilirubin; TDF: Tenofovir; 3TC: Lamivudine. 
Bilirubin values in the image to the right, transaminases to the left.
Figure 2 Portal tracts can be identified but the parenchima has been 
replaced by inflammatory cells (Needle biopsy, H and E).
Figure 3 Heavy portal inflammatory infiltrate. Some hepatocytes have a 
ground-glass appearance (Needle biopsy, H and E).
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CASE REPORT
In January 2015, a 68 years old Caucasian female was evaluated at 
Infectious Disease Unit of University Hospital of Trieste because 
of worsening asthenia, loss of appetite and difficulty eating. 
Physical examination relieved jaundice and tenderness abdomen. 
The laboratory data showed a total bilirubin (TBIL) of 4.34 mg/
dL (direct bilirubin 1.57 mg/dL), Alkaline phosphatase 110 IU/
L, aspartate aminotransferase (AST) 172 IU/ml and alanine 
aminotransferase (ALT) 460 IU/ml.
    About a year before the diagnosis of breast cancer, the patient 
suffered from bone pain. She took not specified doses of steroids 
prescribed by her General Practicioner in that period.
    The diagnosis of invasive ductal carcinoma, Grade 2, with 
evidence of bone metastases was made in the Autumn of 2014.
    The patient had radiation therapy for palliation of bone pain in 
November 2014. She was administered in a repeating cycle of total 
daily doses of 3500 mg of capecitabine orally in a combination 
therapy with 8 mg of methylprednisolone orally in December 2014 
(day 17th and 30th).
    The patient has never shown previously hypertransaminasemia, 
therefore hepatitis markers were never executed. The clinical 
course was characterized by a progressive increase of the indices of 
hepatic necrosis (Figure 1), with onset of hepatic encephalopathy 
(HE). We had, after 3 days of admission, the acquisition of hepatitis 
markers: the patient tested positive for hepatitis B surface antigen 
(HBsAg), HBeAg borderline and anti-hepatitis B core antibodies 
(HBcAb) IgG, and hepatitis A virus antibodies (HAVAb) IgG. The 
patient tested negative for hepatitis B surface antibody (HBsAb), 
HBcAb IgM, anti-human immunodeficiency virus (HIV), HAVAb 
IgM, anti-hepatitis C virus (HCVAb).
    Levels of HBV DNA: 10 e8 IU/ml and quantitative HBsAg: 
42687 IU/mL.
    After the knowledge of the viral etiological profile we started 
immediately antiviral therapy with tenofovir (TDF, 300 mg orally 
once daily) and Lamivudine (3TC, 100 mg orally once daily).
    The patient died of liver failure after 8 days of admission (Figure 
1).
    Hepatic histology was described in the autopsy report, pathologic 
findings: Imposing phenomena of steatosis and hepatic necrosis 
(Figure 2) with multiple foci of lymphocyte inflammation (Figure 3).
DISCUSSION
HBVr in patients undergoing ISDT is a life-threatening event described 
in both HBsAg-positive patients (overt HBV infection)[9]  and HBsAg-
negative but anti-HBc-positive patients (past HBV ifection). Actually 
is consider as moderate/high risk of HBVr, in patients with breast 
cancer, the treatment based on derivatives of anthracyclines such as 
doxorubicin and epirubicin. No mention is made to the capecitabine[10].
    The first flaw of our report is that we don’t know hepatitis 
markers before the admission because the patient was never tested. 
The low rate of screening[11] could be related to the cost of testing, 
the absence of different therapeutic combinations commonly used[4], 
the fact that HBV infection is not considered a major issue in cancer 
patients. The second flow is that we did not exactley know the dose 
of steroids that the patient assumed before chemotherapy. This 
often happens in clinical practice in old cancer patients with many 
diseases associated, although 8 mg of methylprednisolone for two 
day of a chemo-session (17th and 30th of December 2014) represents 
a risk far from HBVr[10]. Strengthening the notion that steroids 
could have a marginal role in HBVr of our patient Salpini et al[12]  in 
a recent large cohort study of HBV-reactivated patients, 51.7% were 
treated with rituximab, 34.5% with different chemotherapeutics, 
and 13.8% with corticosteroids. HBVr after discontinuation of 
ISDT was observed in about half of the patients (48.3%) and was 
positively correlated with patients’ age. Conversely, HBVr after 
discontinuing immunosuppression was negatively correlated with 
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use of corticosteroids. Our patient reactivated in January and 
discontinued therapy in late December. The late onset of HBVr after 
discontinuation of corticosteroids could be explained by the fact 
that the HBV genome contains a glucocorticoid responsive element 
(GRE) whose stimulation enhances the rate of a stable HBV-DNA 
minichromosome named covalently closed circular DNA (cccDNA) 
transcription and, in turn, HBV replication[13]. 
    The incidence of HBVr is a common clinical problem in endemic 
regions. However, the incidence of reactivation is difficult to 
evaluate because of the possible absence of HBV markers testing 
before and during ISDT, lack of standardized nomenclature and 
definitions of HBVr, and variation of the sensitivity and linearity of 
HBV DNA assays used across studies.
    Patients who received antiviral prophylaxis had less interruption 
of chemotherapy and lower rates of cancer-related and all-cause 
mortality. Thus, HBV screening before the start of ISDT is a 
major factor to avoid HBVr[14], because it could be prevented by 
the screening of patients for HBV infection, allowing initiation of 
prophylactic antiviral therapy: In a recent retrospective study, based 
on an electronic pharmacy, Wi et al[15] report the extent of HBV 
screening before chemotherapy and outcomes of screened patients 
at a tertiary oncology center. Thirteen patients were found to have 
HBV infection (1% among tested patients), and prophylactic 
antiviral therapy was used in 8 of these patients. None experienced 
HBVr. According to the authors, the proportion of patients in whom 
undiagnosed HBV infection may have been responsible for the flare 
appeared small. However, results for HBsAg or HBV DNA were 
not available; thus the real incidence of HBVr is unknown.
CONCLUSION
HBV risk tools will be necessary to reduce the risk of HBVr after 
chemotherapy. Guidelines for HBV screening before ISDT are 
controversial. Nevertheless, our case report highlights the need 
to re-evaluate the current HBV screening guidelines for cancer 
patients. HBsAg and anti-HBc assays are sensitive, specific, and 
widely available worldwide at a low cost. Risk-based screening 
is difficult to implement and can miss infected patients who do 
not recognize or report risk factors. So in patients whose medical 
history is unclear, as in our Case Report, screening could be the first 
life-saving procedure.
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